Qi B - Search Results

1

Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents.

Jiang N, Zhai X, Zhao Y, Liu Y, Qi B, Tao H, Gong P. Jiang N, et al. Among authors: qi b. Eur J Med Chem. 2012 Aug;54:534-41. doi: 10.1016/j.ejmech.2012.05.039. Epub 2012 Jun 7. Eur J Med Chem. 2012. PMID: 22727449

2

Synthesis and antiproliferative activity of novel diaryl ureas possessing a 4H-pyrido[1,2-a]pyrimidin-4-one group.

Yao P, Zhai X, Liu D, Qi BH, Tan HL, Jin YC, Gong P. Yao P, et al. Arch Pharm (Weinheim). 2010 Jan;343(1):17-23. doi: 10.1002/ardp.200900130. Arch Pharm (Weinheim). 2010. PMID: 19927308

3

Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.

Qi B, Mi B, Zhai X, Xu Z, Zhang X, Tian Z, Gong P. Qi B, et al. Bioorg Med Chem. 2013 Sep 1;21(17):5246-60. doi: 10.1016/j.bmc.2013.06.026. Epub 2013 Jun 19. Bioorg Med Chem. 2013. PMID: 23838381

4

Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.

Qi B, Tao H, Wu D, Bai J, Shi Y, Gong P. Qi B, et al. Arch Pharm (Weinheim). 2013 Aug;346(8):596-609. doi: 10.1002/ardp.201300087. Epub 2013 Jul 10. Arch Pharm (Weinheim). 2013. PMID: 23843304

5

Identification of novel N¹-(2-aryl-1, 3-thiazolidin-4-one)-N³-aryl ureas showing potent multi-tyrosine kinase inhibitory activities.

Qi B, Yang Y, He H, Yue X, Zhou Y, Zhou X, Chen Y, Liu M, Zhang A, Wei F. Qi B, et al. Eur J Med Chem. 2018 Feb 25;146:368-380. doi: 10.1016/j.ejmech.2018.01.061. Epub 2018 Jan 31. Eur J Med Chem. 2018. PMID: 29407963

6

Discovery of N¹-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N³-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment.

Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T, Wan X, Zhang A, Zhou G. Qi B, et al. Eur J Med Chem. 2019 Feb 1;163:10-27. doi: 10.1016/j.ejmech.2018.11.057. Epub 2018 Nov 23. Eur J Med Chem. 2019. PMID: 30503936

7

Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.

Qi B, Xu X, Yang Y, He H, Yue X. Qi B, et al. Bioorg Med Chem. 2019 Sep 1;27(17):3825-3835. doi: 10.1016/j.bmc.2019.07.016. Epub 2019 Jul 11. Bioorg Med Chem. 2019. PMID: 31307762

8

Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.

Zhou Y, Xu X, Wang F, He H, Gong G, Xiong L, Qi B. Zhou Y, et al. Among authors: qi b. Eur J Med Chem. 2020 Oct 15;204:112643. doi: 10.1016/j.ejmech.2020.112643. Epub 2020 Jul 19. Eur J Med Chem. 2020. PMID: 32731184

9

Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.

Qi B, Wang F, He H, Fan M, Hu L, Xiong L, Gong G, Shi S, Song X. Qi B, et al. Eur J Med Chem. 2022 Sep 5;239:114561. doi: 10.1016/j.ejmech.2022.114561. Epub 2022 Jun 22. Eur J Med Chem. 2022. PMID: 35763868

10

Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2.

Qi B, Xu X, Yang Y, Zhou Y, Chen T, Gong G, Yue X, Xu X, Hu L, He H. Qi B, et al. Bioorg Med Chem. 2019 May 15;27(10):2127-2139. doi: 10.1016/j.bmc.2019.03.049. Epub 2019 Mar 25. Bioorg Med Chem. 2019. PMID: 30940564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,624 results

Search Page

Filters